hydroxyproline has been researched along with pasireotide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albert, R; Bruns, C; Hoyer, D; Kerrad, S; Kneuer, R; Lewis, I; Pless, J; Simeon, C | 1 |
| Accart, N; Beckmann, N; Cannet, C; Dunbar, A; Egger, C; Gérard, C; Jarai, G; Jarman, E; Piaia, A; Schmid, HA; Tigani, B; Vidotto, N | 1 |
2 other study(ies) available for hydroxyproline and pasireotide
| Article | Year |
|---|---|
Medicinal chemistry of somatostatin analogs leading to the DTPA and DOTA conjugates of the multi-receptor-ligand SOM230.
Topics: Chelating Agents; Heterocyclic Compounds, 1-Ring; Humans; Hydroxyproline; Isotope Labeling; Neoplasms; Pentetic Acid; Receptors, Somatostatin; Somatostatin; Technology, Pharmaceutical; Urethane | 2005 |
Lung volume quantified by MRI reflects extracellular-matrix deposition and altered pulmonary function in bleomycin models of fibrosis: effects of SOM230.
Topics: Animals; Bleomycin; Disease Models, Animal; Extracellular Matrix; Hydroxyproline; Inflammation; Lung; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Somatostatin | 2014 |